FDA Calls High Cholesterol a Disease, Not a Risk

what did fda say about hypercholesterolemia in the 2000 rule?

FDA said, in the preamble to its 2000 structure/function rule — DSHEA's framework for normal-function label statements — that elevated cholesterol is a disease in its own right, not a warning sign of one. The exact sentence, from the Federal Register: 'elevated blood pressure (hypertension) and elevated cholesterol (hypercholesterolemia) are diseases themselves, with subsequent events (heart attack, stroke) the late consequences of those diseases.'

That single line reframes the entire vertical.

The rule (65 FR 1000, Docket 98N-0044) took effect February 7, 2000, and it's still the operative text of 21 CFR 101.93. We checked it against the current text and found no amendment to the disease-status language in twenty-six years.

why does calling the marker a disease lower the whole ceiling?

It lowers the ceiling because FDA doesn't treat cholesterol like an ordinary structure/function target — a number to nudge. It treats hypercholesterolemia as the endpoint itself. FDA put it bluntly: 'FDA continues to believe that 'lowers cholesterol,' however qualified, is an implied disease claim,' and applied that standard to every hedge advertisers tried.

Weight loss keeps a narrow overweight-versus-obesity gap to work in; cholesterol has nothing comparable, which is one reason the claim ceiling differs so sharply by condition.

Even 'promotes cholesterol clearance' failed the same test.

how does this differ from treating cholesterol as a risk factor?

It differs completely, because FDA rejected the risk-factor framing rather than adopting it. A risk-factor approach would let a supplement claim to move a number without claiming to treat what the number predicts; FDA's own text closes that door for cholesterol by name.

FTC's compliance guidance draws the same line independently. It groups 'reduces cholesterol' with 'inhibits platelet aggregation' as language that 'are such characteristic signs or symptoms associated with stroke and cardiovascular disease and interventions to treat those diseases' that any claim about them counts as a disease claim — two agencies, two separate legal tests, one identical conclusion.

does the same reasoning apply to blood pressure?

Yes — the rule text proves it in the same breath. FDA named hypertension and hypercholesterolemia together as diseases, not as risk factors for disease, and nothing in the twenty-six years since has separated the two.

The asymmetry sits elsewhere: sodium and hypertension carry an authorized health claim under 21 CFR 101.74, while cholesterol-lowering has no equivalent general claim — only substance-specific coronary heart disease (CHD) risk claims, covered below.

what claims remain available once the marker is a disease?

One structure/function claim survives, and FDA wrote it word for word: 'helps to maintain cholesterol levels that are already within the normal range.' Drop the qualifier and the sentence becomes an implied disease claim; keep it, pair it with the DSHEA disclaimer, and notify FDA's Office of Dietary Supplement Programs within 30 days of first marketing, and the claim sits inside the safe harbor.

A separate track exists for authorized health claims — FDA-approved risk-reduction statements for named substances — but they attach to specific ingredients, not to any formula that wants to borrow them. Soluble fiber, soy protein and plant sterol esters each carry their own CHD risk claim under 21 CFR part 101 subpart E, and none of them says 'lowers cholesterol' — they say a diet containing the substance 'may reduce the risk of' the disease.

We walk through exactly which of those claims an offer can actually use on the cholesterol claims FDA has authorized.

how does the labeling-as-a-whole test get applied?

FDA reads the whole label, not just the sentence carrying the claim. Its own words: 'FDA will review all cholesterol claims to determine whether the labeling as a whole implies that the product is intended to lower elevated cholesterol levels.'

FDA's November 14, 2022 letter to BergaMet North America shows how far that test reaches, and it treated four separate pieces of evidence as equally probative. It cited the product's name, Cholesterol Command, as intended-use evidence under the naming trigger built into 21 CFR 101.93(g)(2)(iv)(A). It cited the express claim printed in the ad, quoting the brand's own copy that '[BergaMet] Cholesterol Command is clinically proven to improve cholesterol levels. It reduces LDL.' It cited the money-back guarantee, which promised a refund 'if they do not improve your LDL levels' — a guarantee, FDA reasoned, is itself a claim. And it cited a third-party Walmart listing describing the product as 'a bergamot supplement for high cholesterol,' language BergaMet never wrote itself but that FDA counted against the file anyway, per the warning letter.

Essential Elements got the same treatment for the opposite reason — over-hedging, not over-claiming. FDA cited both the blunt 'Helps Reduce LDL Levels' and the heavily qualified Amazon line 'aid your body in potentially lowering bad cholesterol levels' as equally probative of drug intent, plus ingredient claims about red yeast rice and garlic powder lowering LDL. Hedge language doesn't read as safer; it reads as the same claim in a softer voice.

what does this mean for an offer already built on ldl copy?

If your offer's core claim is lowering LDL, you're already past the ceiling, and the fix is rewriting to the 'already within the normal range' construction or dropping the claim — not softening the verb. 'Supports' and 'aids' don't move the needle; FDA has already shown it reads hedged claims the same as blunt ones.

Enforcement here arrives in batches. On November 14, 2022, FDA's Center for Food Safety and Applied Nutrition issued five same-day warning letters in the cholesterol and cardiovascular supplement space, all charged as unapproved new drugs:

The trap isn't unique to cholesterol. The same one-sentence collapse from symptom to disease is why the hangover angle reads as a disease claim to FDA in an entirely different vertical, and it's worth checking your own copy against that pattern before a media buy, not after.

One thing we could not verify directly: the full text of FTC's Example 13, on a 'preliminary research suggests' cholesterol hedge, which our source captured in truncated form. Retrieving the complete compliance guidance passage before quoting FTC's conclusion verbatim would settle exactly how far that hedge fails.

• iwi
• BergaMet North America LLC
• Essential Elements
• Chambers' Apothecary
• Anabolic Laboratories Inc.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Private Label Supplements Oklahoma City, Joint Pain Relief Band: What It Is and What It Is Not, Peptide Manufacturing Market: Read Before You Rely on It, Nutraceutical Manufacturing Business for Sale, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.